1052 related articles for article (PubMed ID: 19389019)
1. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.
Sahai A; Dowson C; Khan MS; Dasgupta P
BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
Sahai A; Khan MS; Dasgupta P
J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328
[TBL] [Abstract][Full Text] [Related]
3. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity.
Sahai A; Dowson C; Khan MS; Dasgupta P;
Urology; 2010 Mar; 75(3):552-8. PubMed ID: 20035984
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
[TBL] [Abstract][Full Text] [Related]
6. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
7. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
[TBL] [Abstract][Full Text] [Related]
8. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
Grosse J; Kramer G; Jakse G
BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
[TBL] [Abstract][Full Text] [Related]
9. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
[TBL] [Abstract][Full Text] [Related]
10. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder.
Sahai A; Khan MS; Le Gall N; Dasgupta P;
Urology; 2008 Mar; 71(3):455-9. PubMed ID: 18342186
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units.
Cohen BL; Barboglio P; Rodriguez D; Gousse AE
Neurourol Urodyn; 2009; 28(3):205-8. PubMed ID: 19058190
[TBL] [Abstract][Full Text] [Related]
12. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
[TBL] [Abstract][Full Text] [Related]
13. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.
Kelleher CJ; Cardozo L; Chapple CR; Haab F; Ridder AM
BJU Int; 2005 Jan; 95(1):81-5. PubMed ID: 15638900
[TBL] [Abstract][Full Text] [Related]
14. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of health-related quality of life outcomes with darifenacin.
Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
Jeffery S; Fynes M; Lee F; Wang K; Williams L; Morley R
BJU Int; 2007 Dec; 100(6):1302-6. PubMed ID: 17979928
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
Kuo HC
Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
[TBL] [Abstract][Full Text] [Related]
18. Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury.
Hori S; Patki P; Attar KH; Ismail S; Vasconcelos JC; Shah PJ
BJU Int; 2009 Jul; 104(2):216-20. PubMed ID: 19220255
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
20. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
Kelleher CJ; Tubaro A; Wang JT; Kopp Z
BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
